diazoxide choline · Vykat XR

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Prader-Willi Syndrome

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Development in Obesity stopped as a strategic decision by the sponsor. Development continues in another indication. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Prader-Willi Syndrome
NCT05701774 · Soleno Therapeutics, Inc.
Run by former owner Soleno Therapeutics
2023-01-31 – 2026-04-29 · Prader-Willi Syndrome
What this study did
NCT04086810 · Soleno Therapeutics, Inc.
Run by former owner Soleno Therapeutics
2019-10 – 2019-10 · Prader-Willi Syndrome
What this study did
Other / comorbidity
NCT00973271 · Essentialis, Inc.
2011-03 – 2011-12 · Hypertriglyceridemia
What this study did
Phase 2 (4)
Prader-Willi Syndrome
NCT02893618 · Essentialis, Inc.
2017-07 – 2017-12 · Prader-Willi Syndrome
What this study did
Other / comorbidity
NCT01211847 · Essentialis, Inc.
2010-10 – 2011-12 · Hypertriglyceridemia, Dyslipidemia
What this study did
NCT00696475 · Essentialis, Inc.
2008-06 – 2009-03 · Hypertriglyceridemia
What this study did
Phase 1/2 (1)
Prader-Willi Syndrome
NCT02034071 · Essentialis, Inc.
2014-04 – 2015-05 · Prader-Willi Syndrome
What this study did
Phase 1 (3)
Other / comorbidity
NCT00901823 · Essentialis, Inc.
2011-03 – 2011-03 · Hypertriglyceridemia
What this study did
NCT01211860 · Essentialis, Inc.
2010-10 – 2010-11 · Hypertriglyceridmia
What this study did
NCT00688857 · Essentialis, Inc.
2008-05 – 2008-07 · Hypertriglyceridemia
What this study did

Competitive landscape

This drug's own stage for Prader-Willi Syndrome: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Diazoxide Choline (Vykat XR): this drugApprovedSmall moleculeKATP channelPartial signal
NCT03714373: Primary endpoint (Study 2-RWP, 16-week double-blind randomized withdrawal, 77 patients): change in HQ-CT Total Score at Week 16. The US label reports statistically significant worsening of hyperphagia in the placebo group relative to the VYKAT XR group (label Table 5).
NCT03440814: Hyperphagia Questionnaire (HQ-CT) Change From Baseline at Visit 7 (Week 13) (Baseline to Visit 7 (Week 13)): DCCR -5.94 score on a scale (Standard Error 0.879) vs Placebo for DCCR -4.27 score on a scale (Standard Error 1.145) missed
ARD-101Phase 3Small moleculeBitter taste receptor (gut)Partial signalNo reviewed efficacy summary in this indication
Pitolisant (Wakix)Phase 3Small moleculeHistamine H3 receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
CSTI-500Phase 2Small moleculeSerotonin/norepinephrine/dopamine transporters (SERT/NET/DAT)Weak signal
NCT05504395: Single 10mg oral dose of CSTI-500 capsule formulation in PWS patients at Vanderbilt: no severe adverse events; PK confirmed bioequivalence to prior formulation/healthy-volunteer data; led to Phase 2a advancement.
Setmelanotide (Imcivree)Phase 2PeptideMC4Rnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 April 2026WithdrawalSoleno withdraws EU marketing authorisation application for Viokat (diazoxide choline)
EU, EMA · Soleno Therapeutics · Source ↗
22 May 2025Filing acceptedEMA validates MAA for diazoxide choline prolonged-release tablets
EU, EMA · Source ↗